Order by 3pm for delivery before the Bank Holiday. Orders placed after 3pm will be processed from Tuesday.
Price range: £24.99 through £49.99
For research use only — Not for human or animal use
PT-141 10mg, also known as Bremelanotide, is a synthetic research peptide that has attracted significant scientific interest due to its interaction with the body’s melanocortin receptor system.
Unlike many compounds investigated within reproductive physiology, PT-141 is primarily studied for its activity within the central nervous system rather than direct effects on the vascular system.
This unique mechanism has made PT-141 an important subject within behavioural neuroscience, receptor pharmacology and neuroendocrine research. Scientists continue investigating how activation of specific melanocortin receptors influences neurological communication associated with motivation, behaviour and reproductive physiology.
Our PT-141 10mg Vial is supplied exclusively for laboratory research, analytical testing and scientific investigation. It is not intended for human or veterinary use.
PT-141 Bremelanotide is a synthetic analogue developed from earlier melanocortin-related compounds. During development, researchers discovered that its pharmacological profile differed considerably from compounds investigated primarily for pigmentation, leading to extensive research into receptor activity within the brain.
PT-141 acts as a melanocortin receptor agonist, interacting predominantly with MC3R and MC4R receptors found within regions of the hypothalamus and other parts of the central nervous system. These receptors regulate numerous physiological signalling pathways, making them valuable targets for experimental research.
Because of this receptor selectivity, PT-141 continues to be investigated across several scientific disciplines, including behavioural neuroscience, endocrinology and neuropharmacology. It also forms part of a wider group of research peptides used to investigate receptor-mediated biological processes.
Unlike research compounds that primarily influence vascular responses, PT-141 is investigated for the way it interacts with neuronal signalling pathways. This distinction allows scientists to explore how receptor activation contributes to behavioural responses without relying on direct blood vessel dilation.
Current research examines how melanocortin receptor activation may contribute to understanding:
These investigations remain experimental and continue to improve scientific understanding of receptor-mediated neurological signalling.
Published literature suggests PT-141 acts by stimulating melanocortin receptors involved in complex neurological signalling networks. Rather than producing a direct vascular response, researchers believe receptor activation influences communication between multiple areas of the brain associated with behavioural regulation.
This mechanism has generated considerable scientific interest because it represents a fundamentally different research pathway compared with compounds investigated primarily for circulatory effects.
Researchers continue exploring how this receptor activity relates to sexual function, behavioural responses and neurological communication under controlled laboratory conditions.
Modern PT-141 research extends well beyond a single biological question. Published studies continue investigating:
Researchers also continue examining how receptor activation may contribute to a broader understanding of sexual health and behavioural signalling across different experimental models.
One reason PT-141 has received considerable attention is that its mechanism differs from compounds traditionally investigated for vascular activity. Scientific literature frequently compares these different approaches to better understand how neurological signalling and physiological responses interact.
Discussions surrounding blood flow PT-141 generally arise within comparative studies, where researchers evaluate neurological receptor activation alongside vascular mechanisms. This distinction remains one of the defining characteristics of Bremelanotide research.
Research investigating desire PT-141 continues to expand through both laboratory and clinical studies. Scientists are particularly interested in how melanocortin receptor activation influences behavioural pathways associated with sexual activity, motivation and reproductive physiology.
Scientific publications also document experimental observations relating to pharmacokinetics, receptor affinity and reported side effects.
These findings remain specific to individual studies and contribute to the wider body of published scientific literature rather than establishing therapeutic conclusions. Researchers often compare these findings with evidence gathered from other research peptides investigating different signalling pathways.
Our PT-141 10mg Vial is supplied as a lyophilised peptide powder for laboratory handling and analytical testing. Preparation should be performed using validated laboratory procedures appropriate to the experimental protocol.
For optimum stability, store unopened vials at -20°C in a dry environment protected from moisture and direct sunlight. Following reconstitution, laboratories should follow recognised storage procedures suitable for their individual research applications.
This product is supplied strictly for laboratory research, analytical testing and scientific investigation. The information provided on this page is for educational purposes summarising published scientific literature only.
PT-141 is not intended for human consumption, veterinary use, diagnosis or therapeutic application. Browse our complete range of research peptides to explore additional compounds available for laboratory investigation.
Discount Applied Successfully!
Your savings have been added to the cart.
